I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
hypertension
left ventricular end-diastolic pressure
septal defect
ventricular septal defect
atrial septal defect
- 0 views
- 16 Feb, 2024
- 211 locations